Aberrant Methylation of FOXE1 Contributes to a Poor Prognosis for Patients with Colorectal Cancer

Keishi Sugimachi, Tae Matsumura, Teppei Shimamura, Hidenari Hirata, Ryutaro Uchi, Masami Ueda, Shotaro Sakimura, Tomohiro Iguchi, Hidetoshi Eguchi, Takaaki Masuda, Kazutoyo Morita, Kenji Takenaka, Yoshihiko Maehara, Masaki Mori, Koshi Mimori

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Hypermethylation of DNA silences gene expression and is an important event in colorectal cancer (CRC). This study aimed to identify aberrantly methylated genes that contribute to a poor prognosis for patients with CRC. Methods: The study comprehensively explored DNA methylation microarray profiles from 396 CRC samples and 45 normal control samples in a database and selected aberrantly methylated transcription factors associated with prognosis and metastasis. Using quantitative reverse transcription polymerase chain reaction, the identified genes in 140 patients with CRC were validated to assess the relationship between expression of methylated genes and prognosis. Results: In the study, FOXE1 was newly identified as a gene associated with prognosis and metastasis in CRC. Expression of FOXE1 in CRC tissues was significantly lower than in normal colorectal tissues (p = 0.01). The survival rate for the patients with low expression of FOXE1 was significantly lower than that for patients with high expression of FOXE1 in uni- and multivariate analyses. Inhibition of DNA methylation recovered FOXE1 expression in CRC cells. Conclusions: Methylation-mediated silencing of FOXE1 expression was shown to be a potential prognostic factor in CRC.

Original languageEnglish
Pages (from-to)3948-3955
Number of pages8
JournalAnnals of Surgical Oncology
Volume23
Issue number12
DOIs
Publication statusPublished - Nov 1 2016

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this